These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 17983801)

  • 21. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation.
    Fung SK; Andreone P; Han SH; Rajender Reddy K; Regev A; Keeffe EB; Hussain M; Cursaro C; Richtmyer P; Marrero JA; Lok AS
    J Hepatol; 2005 Dec; 43(6):937-43. PubMed ID: 16168522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
    Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N
    J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil.
    Chen CH; Wang JH; Lee CM; Hung CH; Hu TH; Wang JC; Lu SN; Changchien CS
    Antivir Ther; 2006; 11(6):771-8. PubMed ID: 17310821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
    Heo NY; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Hepatol; 2010 Sep; 53(3):449-54. PubMed ID: 20646776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    Intervirology; 2008; 51(6):385-93. PubMed ID: 19229115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
    Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
    J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.
    Buti M; Elefsiniotis I; Jardi R; Vargas V; Rodriguez-Frias F; Schapper M; Bonovas S; Esteban R
    J Hepatol; 2007 Sep; 47(3):366-72. PubMed ID: 17561304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Virologic response and resistance to adefovir in patients with chronic hepatitis B.
    Fung SK; Chae HB; Fontana RJ; Conjeevaram H; Marrero J; Oberhelman K; Hussain M; Lok AS
    J Hepatol; 2006 Feb; 44(2):283-90. PubMed ID: 16338024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine resistance.
    Shin JW; Jung SW; Park BR; Kim CJ; Eum JB; Kim BG; Du Jeong I; Bang SJ; Park NH
    Antivir Ther; 2012; 17(2):387-94. PubMed ID: 22293395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
    Rapti I; Dimou E; Mitsoula P; Hadziyannis SJ
    Hepatology; 2007 Feb; 45(2):307-13. PubMed ID: 17256746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy.
    Reijnders JG; Pas SD; Schutten M; de Man RA; Janssen HL
    J Hepatol; 2009 Apr; 50(4):674-83. PubMed ID: 19231002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment.
    Moriconi F; Colombatto P; Coco B; Ciccorossi P; Oliveri F; Flichman D; Maina AM; Sacco R; Bonino F; Brunetto MR
    J Antimicrob Chemother; 2007 Aug; 60(2):341-9. PubMed ID: 17567633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to adefovir depends on mutation patterns in precore region, basal core promoter and reverse transcriptase, and on-treatment responses in Lamivudine-resistant chronic hepatitis B patients.
    Song BC; Cui XJ; Shin JW; Park NH; Cho YK; Song HJ; Hyun S; Jeong SU; Choi EK; Kim HU
    Intervirology; 2010; 53(4):203-10. PubMed ID: 20332649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients.
    Idilman R; Kaymakoglu S; Oguz Onder F; Ahishali E; Bektas M; Cinar K; Pinarbasi B; Karayalcin S; Badur S; Cakaloglu Y; Mithat Bozdayi A; Bozkaya H; Okten A; Yurdaydin C
    J Viral Hepat; 2009 Apr; 16(4):279-85. PubMed ID: 19222742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.
    Corsa AC; Liu Y; Flaherty JF; Mitchell B; Fung SK; Gane E; Miller MD; Kitrinos KM
    Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2106-12.e1. PubMed ID: 24929235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy.
    Ijaz S; Arnold C; Dervisevic S; Mechurova J; Tatman N; Tedder RS; Naoumov NV
    J Med Virol; 2008 Jul; 80(7):1160-70. PubMed ID: 18461609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience.
    Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
    Liver Int; 2011 Feb; 31(2):206-14. PubMed ID: 21143368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
    Cho YK; Cui XJ; Jeong SU; Song BC
    Antiviral Res; 2014 Dec; 112():8-17. PubMed ID: 25303802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy.
    Mihm U; Gärtner BC; Faust D; Hofmann WP; Sarrazin C; Zeuzem S; Herrmann E
    J Hepatol; 2005 Aug; 43(2):217-24. PubMed ID: 15964093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simple scoring system predicting genotypic resistance during rescue therapy for Lamivudine-resistant chronic hepatitis B.
    Lee JH; Yoon JH; Cho EJ; Yang HJ; Jang ES; Kwak MS; Hwang SY; Yu SJ; Lee CH; Kim YJ; Kim CY; Lee HS
    J Clin Gastroenterol; 2012 Mar; 46(3):243-50. PubMed ID: 21716122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.